Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma

The efficacy of daratumumab depends partially on CD38 expression on multiple myeloma (MM) cells. We have previously shown that all-trans retinoic acid (ATRA) upregulates CD38 expression and reverts daratumumab-resistance ex vivo. We therefore evaluated the optimal dose, efficacy, and safety of darat...

Descripción completa

Detalles Bibliográficos
Autores principales: Frerichs, Kristine A., Minnema, Monique C., Levin, Mark-David, Broijl, Annemiek, Bos, Gerard M. J., Kersten, Marie José, Mutis, Tuna, Verkleij, Christie P. M., Nijhof, Inger S., Maas-Bosman, Patricia W. C., Klein, Saskia K., Zweegman, Sonja, Sonneveld, Pieter, van de Donk, Niels W. C. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153006/
https://www.ncbi.nlm.nih.gov/pubmed/34625791
http://dx.doi.org/10.1182/bloodadvances.2021005220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153006/
https://www.ncbi.nlm.nih.gov/pubmed/34625791
http://dx.doi.org/10.1182/bloodadvances.2021005220

Ejemplares similares